---
document_datetime: 2024-05-13 12:21:34
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/telmisartan-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: telmisartan-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.2534482
conversion_datetime: 2025-12-20 01:37:50.071937
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Telmisartan Actavis

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0031            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 23/04/2024                          |                                             | Annex II and PL                  |           |
| N/0029               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 23/10/2023                          |                                             | Labelling and                    |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                          |            |     | PL                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| IG/1612   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                               | 31/05/2023 |     | SmPC, Labelling and PL |
| IB/0027   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                              | 08/11/2022 | n/a |                        |
| IA/0026   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                              | 23/05/2022 | n/a |                        |
| IB/0025   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                             | 08/04/2022 | n/a |                        |
| N/0024    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                         | 24/09/2021 |     | PL                     |
| IB/0022/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 24/02/2021 | n/a |                        |

<div style=\"page-break-after: always\"></div>

|           | the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                  |            |            |                       | B.I.b.1.h - Change in   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------|
| IA/0021   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/12/2020 | 22/09/2021 | Annex II and PL       |                         |
| IB/0020   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                       | 18/09/2020 | 22/09/2021 | SmPC, Annex II and PL |                         |
| IB/0019/G | This was an application for a group of variations. B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 22/07/2020 | n/a        |                       |                         |
| N/0018    | Minor change in labelling or package leaflet not                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 21/08/2018 | 22/09/2021 | PL                    |                         |

<div style=\"page-break-after: always\"></div>

|           | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                            |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0017    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                           | 20/03/2018 | 22/09/2021 | Labelling and PL      |                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0016   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                | 27/02/2017 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                       |
| N/0015    | Update of the package leaflet with revised contact details of the local representatives for Belgium, Bulgaria, Germany, Spain, France, Croatia, Luxembourg and the Netherlands. In addition, the MAH took the opportunity to make linguistic and editorial amendments to the French, Estonian, Dutch, Lithuanian, Finnish, Czech, Latvian and Hungarian package leaflets. Minor change in labelling or package leaflet not | 05/07/2016 | 22/09/2021 | PL                    |                                                                                                                                                                                                                                                                                                                                                                       |
| R/0014    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                    | 23/04/2015 | 19/06/2015 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the CHMP considered that the benefit-risk balance of Telmisartan Actavis in the approved indications remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0013/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                         | 01/12/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                    |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012/G | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                            | 17/11/2014 | n/a        |             |                                                                                                                                    |
| A31/0007  | On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit- risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure. | 22/05/2014 | 04/09/2014 | SmPC and PL | For further information please refer to the Renin- angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report. |

<div style=\"page-break-after: always\"></div>

| IB/0011            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                 | 23/04/2014   | 04/09/2014   | SmPC and PL           |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|-----------------------------------|
| IB/0010/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 21/11/2013   | 04/09/2014   | SmPC, Annex II and PL |                                   |
| PSUSA/2882/ 201304 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/11/2013   | n/a          |                       | PRAC Recommendation - maintenance |
| IB/0008            | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29/07/2013   | 04/09/2014   | SmPC and PL           |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0006   | Update of SmPC and package leaflet following CHMP adoption on 19 April 2012 of safety variations to the Marketing Authorisations for Micardis, Pritor and Kinzalmono. Amendments in line with the originator, the current QRD template (Version 8, 07/2011; Rev. 1, 10/2011) and minor editorial amendments are proposed in sections 2, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1, 5.2, 6.6 of the SmPC, Annex II, section 6 of the Labelling, and all sections of the Package Leaflet. Additionally, Package Leaflet is updated with the details of local representatives for CZ, PL, EL, NL, SI, CY. Furthermore, corrections in the translations were made for the following countries: DE, EL, FR, IS, MT and SI to be in line with the originator. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO   | 26/07/2012   | 04/09/2014   | SmPC, Annex II, Labelling and PL   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|
| IB/0005/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.1.b - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/02/2012   | n/a          |                                    |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.III.2.a.1 - Change of specification('s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation   |            |     |                                  |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|
| IB/0004   | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 02/12/2011 | n/a |                                  |
| IAIN/0003 | B.III.1.a.1 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                     | 17/11/2011 | n/a |                                  |
| IB/0002/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                               | 06/10/2011 | n/a | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|